Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Acquired by Barclays PLC

Barclays PLC grew its holdings in Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 14.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 191,954 shares of the company’s stock after acquiring an additional 24,236 shares during the period. Barclays PLC’s holdings in Atossa Therapeutics were worth $181,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in ATOS. Gallagher Capital Advisors LLC purchased a new position in Atossa Therapeutics during the fourth quarter valued at $25,000. Intech Investment Management LLC increased its position in Atossa Therapeutics by 224.0% during the fourth quarter. Intech Investment Management LLC now owns 62,844 shares of the company’s stock worth $59,000 after purchasing an additional 43,449 shares during the last quarter. Wells Fargo & Company MN increased its position in Atossa Therapeutics by 30.7% during the fourth quarter. Wells Fargo & Company MN now owns 71,720 shares of the company’s stock worth $68,000 after purchasing an additional 16,853 shares during the last quarter. SG Americas Securities LLC increased its position in Atossa Therapeutics by 148.2% during the fourth quarter. SG Americas Securities LLC now owns 103,865 shares of the company’s stock worth $98,000 after purchasing an additional 62,016 shares during the last quarter. Finally, Virtu Financial LLC increased its position in shares of Atossa Therapeutics by 311.1% during the fourth quarter. Virtu Financial LLC now owns 208,196 shares of the company’s stock valued at $197,000 after acquiring an additional 157,549 shares during the last quarter. 12.74% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently commented on ATOS. HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Atossa Therapeutics in a research note on Wednesday, March 26th. Ascendiant Capital Markets raised their price objective on shares of Atossa Therapeutics from $7.00 to $7.25 and gave the stock a “buy” rating in a report on Monday, April 21st.

Atossa Therapeutics Price Performance

NASDAQ ATOS opened at $0.84 on Tuesday. Atossa Therapeutics, Inc. has a 12 month low of $0.55 and a 12 month high of $1.71. The company has a 50-day moving average of $0.71 and a 200-day moving average of $0.93. The company has a market cap of $108.10 million, a P/E ratio of -3.80 and a beta of 1.01.

Atossa Therapeutics (NASDAQ:ATOS) last released its quarterly earnings results on Tuesday, March 25th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. As a group, equities research analysts anticipate that Atossa Therapeutics, Inc. will post -0.22 EPS for the current year.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.